Koizumi Eriko, Goto Osamu, Matsuda Akihisa, Otsuka Toshiaki, Ishikawa Yumiko, Nakagome Shun, Niikawa Masahiro, Habu Tsugumi, Yoshikata Keiichiro, Kirita Kumiko, Noda Hiroto, Higuchi Kazutoshi, Onda Takeshi, Omori Jun, Akimoto Naohiko, Yoshida Hiroshi, Iwakiri Katsuhiko
Department of Gastroenterology, Nippon Medical School, Graduate School of Medicine, Tokyo, Japan.
Endoscopy Center, Nippon Medical School Hospital, Tokyo, Japan.
Dig Endosc. 2025 Mar;37(3):236-246. doi: 10.1111/den.14933. Epub 2024 Oct 6.
This systematic review and meta-analysis aimed to evaluate the diagnostic ability and examine the efficacy of countermeasures to adverse events of mucosal incision-assisted biopsy (MIAB) for gastric subepithelial tumors (SETs).
We performed a literature search and identified 533 relevant articles. Eleven articles, including 339 lesions, were ultimately used in the meta-analysis. The primary end-point was the pathological diagnostic rate of MIAB for gastric SETs, and the secondary end-point was the incidence of adverse events. The efficacy of acid secretion inhibitors in preventing postoperative bleeding and that of local injection before incision to prevent perforation were also examined.
Nine studies were conducted in Japan and two in South Korea, of which only two were prospective studies. The pooled pathological diagnostic rate of MIAB for gastric SETs was 87.8% (95% confidence interval [CI] 80.2-94.0; I = 68.7%). The adverse event rate of the pooled population was 0.2% (95% CI 0-1.4; I = 0%). The acid secretion inhibitors significantly reduced postoperative bleeding (odds ratio 0.06, 95% CI 0.01-0.66, P = 0.02). Perforation occurred in 0% and 2.6% of the local and nonlocal injection cohorts, respectively, and the pathological diagnostic rates were 50% and 66.7%, respectively.
MIAB is a reliable technique with a favorable diagnostic rate and few adverse events. Acid secretion inhibitors may effectively prevent postoperative bleeding; however, the efficacy of local injection remains unclear. This technique could be an option for tissue sampling in gastric SETs.
本系统评价和荟萃分析旨在评估黏膜切开辅助活检(MIAB)对胃上皮下肿瘤(SETs)的诊断能力,并检验其对不良事件的应对效果。
我们进行了文献检索,共识别出533篇相关文章。最终,11篇文章(包含339个病灶)被纳入荟萃分析。主要终点是MIAB对胃SETs的病理诊断率,次要终点是不良事件的发生率。我们还检验了胃酸分泌抑制剂预防术后出血的效果以及切开前局部注射预防穿孔的效果。
9项研究在日本开展,2项在韩国开展,其中仅有2项为前瞻性研究。MIAB对胃SETs的合并病理诊断率为87.8%(95%置信区间[CI]80.2 - 94.0;I = 68.7%)。汇总人群的不良事件发生率为0.2%(95%CI 0 - 1.4;I = 0%)。胃酸分泌抑制剂显著降低了术后出血(比值比0.06,95%CI 0.01 - 0.66;P = 0.02)。局部注射组和非局部注射组的穿孔发生率分别为0%和2.6%,病理诊断率分别为50%和66.7%。
MIAB是一种可靠的技术,诊断率良好且不良事件较少。胃酸分泌抑制剂可能有效预防术后出血;然而,局部注射的效果仍不明确。该技术可作为胃SETs组织采样的一种选择。